Up the stairs to the entrance of the plane they climb: small children with cloudy eyes, teens with thick glasses and practiced squints, adults with dark shades.

Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.

Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world.

With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Meet a Senior Medical Director at Novartis who is part of our new “Women in Science” series

Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.